Benzinga's Top #PreMarket Losers
November 25, 2013 at 08:20 AM EST
Celldex Therapeutics (NASDAQ: CLDX ) dipped 9.47% to $25.63 in the pre-market session after the company reported positive Phase 2 rindopepimut data in patients with recurrent glioblastoma. J. C. Penney Company (NYSE: JCP ) dipped 2.59% to $8.64. J.C. Penney will leave the Standard & Poor's 500 index. The retailer
